Literature DB >> 12556445

A molecular docking strategy identifies Eosin B as a non-active site inhibitor of protozoal bifunctional thymidylate synthase-dihydrofolate reductase.

Chloé E Atreya1, Eric F Johnson, John J Irwin, Antonia Dow, Kristen M Massimine, Isabelle Coppens, Valeska Stempliuk, Stephen Beverley, Keith A Joiner, Brian K Shoichet, Karen S Anderson.   

Abstract

Protozoal parasites are unusual in that their thymidylate synthase (TS) and dihydrofolate reductase (DHFR) enzymes exist on a single polypeptide. In an effort to probe the possibility of substrate channeling between the TS and DHFR active sites and to identify inhibitors specific for bifunctional TS-DHFR, we used molecular docking to screen for inhibitors targeting the shallow groove connecting the two active sites. Eosin B is a 100 microm non-active site inhibitor of Leishmania major TS-DHFR identified by molecular docking. Eosin B slows both the TS and DHFR reaction rates. When Arg-283, a key residue to which eosin B is predicted to bind, is mutated to glutamate, however, eosin B only minimally inhibits the TS-DHFR reaction. Additionally, eosin B was found to be a 180 microm inhibitor of Toxoplasma gondii in both biochemical and cell culture assays.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12556445     DOI: 10.1074/jbc.M212690200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Eosin B as a novel antimalarial agent for drug-resistant Plasmodium falciparum.

Authors:  Kristen M Massimine; Michael T McIntosh; Lanxuan T Doan; Chloé E Atreya; Stephan Gromer; Worachart Sirawaraporn; David A Elliott; Keith A Joiner; R Heiner Schirmer; Karen S Anderson
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Disruption of the crossover helix impairs dihydrofolate reductase activity in the bifunctional enzyme TS-DHFR from Cryptosporidium hominis.

Authors:  Melissa A Vargo; W Edward Martucci; Karen S Anderson
Journal:  Biochem J       Date:  2009-02-01       Impact factor: 3.857

3.  Virtual screening reveals allosteric inhibitors of the Toxoplasma gondii thymidylate synthase-dihydrofolate reductase.

Authors:  Hitesh Sharma; Mark J Landau; Todd J Sullivan; Vidya P Kumar; Markus K Dahlgren; William L Jorgensen; Karen S Anderson
Journal:  Bioorg Med Chem Lett       Date:  2013-12-31       Impact factor: 2.823

4.  First three-dimensional structure of Toxoplasma gondii thymidylate synthase-dihydrofolate reductase: insights for catalysis, interdomain interactions, and substrate channeling.

Authors:  Hitesh Sharma; Mark J Landau; Melissa A Vargo; Krasimir A Spasov; Karen S Anderson
Journal:  Biochemistry       Date:  2013-10-03       Impact factor: 3.162

Review 5.  Folate metabolic pathways in Leishmania.

Authors:  Tim J Vickers; Stephen M Beverley
Journal:  Essays Biochem       Date:  2011       Impact factor: 8.000

Review 6.  Dihydrofolate reductase, thymidylate synthase, and serine hydroxy methyltransferase: successful targets against some infectious diseases.

Authors:  Hina Shamshad; Rowaida Bakri; Agha Zeeshan Mirza
Journal:  Mol Biol Rep       Date:  2022-03-07       Impact factor: 2.742

7.  Glutathione reductase-null malaria parasites have normal blood stage growth but arrest during development in the mosquito.

Authors:  Rebecca Pastrana-Mena; Rhoel R Dinglasan; Blandine Franke-Fayard; Joel Vega-Rodríguez; Mariela Fuentes-Caraballo; Abel Baerga-Ortiz; Isabelle Coppens; Marcelo Jacobs-Lorena; Chris J Janse; Adelfa E Serrano
Journal:  J Biol Chem       Date:  2010-06-23       Impact factor: 5.157

8.  A Study of Synergy of Combination of Eosin B with Chloroquine, Artemisinin, and Sulphadoxine-Pyrimethamine on Plasmodium falciparum In Vitro and Plasmodium berghei In Vivo.

Authors:  Sedigheh Sadeghi; Zarrintaj Valadkhani; Alireza Sadeghi Tafreshi; Mohammad Arjmand; Hossein Nahravanian; Farideh Vahabi; Neda Soori; Maryam Mohammadi; Masoomeh Meigooni; Zahra Zamani
Journal:  J Trop Med       Date:  2020-06-01

9.  Efficacy of eosin B as a new antimalarial drug in a murine model.

Authors:  Zahra Zamani; Alireza Sadeghi Tafreshi; Hossein Nahrevanian; Behzad Lame-Rad; Fatemeh Pourfallah; Hossein Eslamifar; Sedigheh Sadeghi; Farideh Vahabi; Ayda Iravani; Mohammad Arjmand
Journal:  Malar Res Treat       Date:  2012-12-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.